Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias (original) (raw)

• Socie G, Clift RA, Blaise D et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569–3574.
  Article CAS PubMed Google Scholar
• Stockerl-Goldstein KE, Blume KG . Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Thomas ED, Blume KG, Forman SJ (eds.). Hematopoietic Cell Transplantation, 2nd edn. Blackwell Science, Inc.: Oxford, 1999; pp. 823–834.
  Google Scholar
• Clift RA, Storb R . Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996; 17 (Suppl. 3): S1–S3.
  PubMed Google Scholar
• Horowitz MM, Rowlings PA, Passweg JR . Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17(Suppl. 3): S5–S6.
  PubMed Google Scholar
• Gratwohl A, Hermans J . Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17(Suppl. 3): S7–S9.
  PubMed Google Scholar
• Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347–1353.
  Article CAS PubMed Google Scholar
• Tutschka PJ, Copelan EA, Klein JP . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–1388.
  CAS PubMed Google Scholar
• Copelan EA, Biggs JC, Thompson JM et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 838–843.
  CAS PubMed Google Scholar
• Geller RB, Saral R, Piantadosi S et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 1989; 73: 2209–2218.
  CAS PubMed Google Scholar
• Essell JH, Thompson JM, Harman GS et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784–2788.
  CAS PubMed Google Scholar
• Biggs JC, Szer J, Crilley P et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992; 80: 1352–1357.
  CAS PubMed Google Scholar
• Blaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578–2582.
  CAS PubMed Google Scholar
• Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036–2043.
  CAS PubMed Google Scholar
• Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723–2730.
  CAS PubMed Google Scholar
• Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85: 2263–2268.
  CAS PubMed Google Scholar
• Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan–cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993; 81: 2187–2193.
  CAS PubMed Google Scholar
• Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867–1871.
  CAS PubMed Google Scholar
• Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77: 1660–1665.
  CAS PubMed Google Scholar
• Bieri S, Helg C, Chapuis B, Miralbell R . Total body irradiation before allogeneic bone marrow transplantation: is more dose better? Int J Radiat Oncol Biol Phys 2001; 49: 1071–1077.
  Article CAS PubMed Google Scholar
• Appelbaum FR, Matthews DC, Eary JF et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54: 829–833.
  Article CAS PubMed Google Scholar
• Matthews DC, Appelbaum FR, Eary JF et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94: 1237–1247.
  CAS PubMed Google Scholar
• Matthews DC, Appelbaum FR, Eary JF et al. 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission. Blood 1996; 88 (Suppl. 1): 142a (Abstr. 556).
  Google Scholar
• Bunjes D, Buchmann I, Duncker C et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I–II study. Blood 2001; 98: 565–572.
  Article CAS PubMed Google Scholar
• Tanimoto M, Scheinberg DA, Cordon-Cardo C et al. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 1989; 3: 339–348.
  CAS PubMed Google Scholar
• Scheinberg DA, Lovett D, Divgi CR et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; 9: 478–490.
  Article CAS PubMed Google Scholar
• Co MS, Avdalovic NM, Caron PC et al. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992; 148: 1149–1154.
  CAS PubMed Google Scholar
• Caron PC, Jurcic JG, Scott AM et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994; 83: 1760–1768.
  CAS PubMed Google Scholar
• Schwartz MA, Lovett DR, Redner A et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993; 11: 294–303.
  Article CAS PubMed Google Scholar
• Jurcic JG, Caron PC, Nikula TK et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 1995; 55(Suppl. 23): 5908s–5910s.
  CAS PubMed Google Scholar
• Caron PC, Co MS, Bull MK et al. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992; 52: 6761–6767.
  CAS PubMed Google Scholar
• Nikula TK, Bocchia M, Curcio MJ et al. Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol 1995; 32: 865–872.
  Article CAS PubMed Google Scholar
• Forman SJ, Blume KG, Krance RA et al. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone. Transplant Proc 1987; 19 (1 Part 3): 2605–2607.
  CAS PubMed Google Scholar
• Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
  Article CAS PubMed Google Scholar
• Society of Nuclear Medicine. MIRD Primer for Absorbed Dose Calculations. Society of Nuclear Medicine: New York, NY; 1988.
• Scheinberg DA, Straus DJ, Yeh SD et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. J Clin Oncol 1990; 8: 792–803.
  Article CAS PubMed Google Scholar
• National Cancer Institute. Common toxicity criteria version 2.0. 1999: http://ctep.cancer.gov/reporting/ctc.html.
• Jones RJ, Lee KS, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778–783.
  Article CAS PubMed Google Scholar
• Blaise D, Maraninchi D, Michallet M et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 2001; 97: 3669–3671.
  Article CAS PubMed Google Scholar
• Clift RA, Radich J, Appelbaum FR et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999; 94: 3960–3962.
  CAS PubMed Google Scholar
• Ringden O, Remberger M, Ruutu T et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196–2201.
  CAS PubMed Google Scholar
• Champlin R, Khouri I, Anderlini P et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 2001; 27 (Suppl. 2): S13–S22.
  Article PubMed Google Scholar
• Papadopoulos EB, Carabasi MH, Castro-Malaspina H et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083–1090.
  CAS PubMed Google Scholar
• Scheinberg DA, Strand M . Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. Cancer Res 1983; 43: 265–272.
  CAS PubMed Google Scholar
• Jurcic JG, Divgi CR, McDevitt MR et al. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia. Proc Am Soc Clin Oncol 2000; 19: 8a (Abstr. 24).
  Google Scholar